Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs

Andersson, 1990, Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding, J Neural Transm Gen Sect, 79, 215, 10.1007/BF01245132 Andreassen, 2000, Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?, Prog Neurobiol, 61, 525, 10.1016/S0301-0082(99)00064-7 Aparicio-Legarza, 1998, Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients, Neurosci Lett, 241, 143, 10.1016/S0304-3940(98)00017-2 Blanchet, 2012, Relevance of animal models to human tardive dyskinesia, Behav Brain Funct, 8, 12, 10.1186/1744-9081-8-12 Boja, 1995, Selective labeling of the dopamine transporter by the high affinity ligand 3 β-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester, Mol Pharmacol, 47, 779 Burnet, 1996, The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain, Neuroscience, 73, 531, 10.1016/0306-4522(96)00062-0 Calon, 2002, Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment, Prog Neuropsychopharmacol Biol Psychiatry, 26, 127, 10.1016/S0278-5846(01)00237-8 Calon, 2003, Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease, Neurobiol Dis, 14, 404, 10.1016/j.nbd.2003.07.003 Cenci, 2010, Maladaptive striatal plasticity in L-DOPA-induced dyskinesia, Prog Brain Res, 183, 209, 10.1016/S0079-6123(10)83011-0 Creed, 2013, Neurobiological basis of dyskinetic effects induced by antipsychotics: the contribution of animal models, Curr Med Chem, 20, 389 Creed-Carson, 2011, Effects of 5-HT2A and 5-HT2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats, Behav Brain Res, 219, 273, 10.1016/j.bbr.2011.01.025 Cyr, 1998, Gonadal hormones modulate 5-hydroxytryptamine2A receptors: emphasis on the rat frontal cortex, Neuroscience, 83, 829, 10.1016/S0306-4522(97)00445-4 Dean, 2002, Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue, Postgrad Med J, 78, 142, 10.1136/pmj.78.917.142 Dean, 2003, The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice, J Neurochem, 85, 1, 10.1046/j.1471-4159.2003.01693.x Eastwood, 1997, Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes, Mol Psychiatry, 2, 322, 10.1038/sj.mp.4000238 Egan, 1996, Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol, Psychopharmacology, 127, 337, 10.1007/s002130050095 Fusar-Poli, 2013, Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density, Schizophr Bull, 39, 22, 10.1093/schbul/sbr111 Gandolfi, 2003, Repeated administration of the novel antipsychotic olanzapine does not modulate NMDA-sensitive glutamate and 5-HT2 serotonin receptors in rats, Naunyn Schmiedebergs Arch Pharmacol, 367, 615, 10.1007/s00210-003-0761-0 Gardoni, 2008, Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor composition in rat striatum, Eur Neuropsychopharmacol, 18, 531, 10.1016/j.euroneuro.2007.10.004 Gomez-Mancilla, 1991, Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys, J Pharmacol Exp Ther, 259, 409 Gray, 2001, Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists, Brain Res Bull, 56, 441, 10.1016/S0361-9230(01)00623-2 Grégoire, 2011, The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys, Parkinsonism Relat Disord, 17, 270, 10.1016/j.parkreldis.2011.01.008 Guay, 2010, Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders, Am J Geriatr Pharmacother, 8, 331, 10.1016/j.amjopharm.2010.08.006 Gupta, 2005, Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia, Synapse, 57, 123, 10.1002/syn.20164 Hamid, 1998, Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia, Brain Res, 796, 291, 10.1016/S0006-8993(98)00196-6 Hintermann, 2007, ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies, Bioorg Med Chem, 15, 903, 10.1016/j.bmc.2006.10.038 Huang, 2007, Effect of chronic treatment with clozapine and haloperidol on 5-HT2A and 2C receptor mRNA expression in the rat brain, Neurosci Res, 59, 314, 10.1016/j.neures.2007.08.001 Konitsiotis, 2006, Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias, Psychopharmacology, 185, 369, 10.1007/s00213-006-0348-9 Kuoppamaki, 1995, Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs, Neuropsychopharmacology, 13, 139, 10.1016/0893-133X(95)00049-J Kusumi, 2000, Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain, J Neural Transm, 107, 295, 10.1007/s007020050024 Lagière, 2013, Serotonin2C receptors and the motor control of oral activity, Curr Neuropharmacol, 11, 160, 10.2174/1570159X11311020003 Lerner, 2015, Tardive dyskinesia (syndrome): Current concept and modern approaches to its management, Psychiatry Clin Neurosci, 69, 321, 10.1111/pcn.12270 Leucht, 2013, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet, 382, 951, 10.1016/S0140-6736(13)60733-3 Lidow, 1995, Clozapine, haloperidol and remoxipride differentially regulate 5-HT2-serotoninergic sites in the primate cerebral cortex, Schizophrenia Res, 15, 158, 10.1016/0920-9964(95)95490-Z Lidow, 2001, Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex, Biol Psychiatry, 49, 1, 10.1016/S0006-3223(00)01058-1 Lieberman, 2008, Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection, Pharmacol Rev, 60, 358, 10.1124/pr.107.00107 Lister, 2014, Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies, Psychopharmacology, 231, 2237, 10.1007/s00213-014-3582-6 Lopez-Gimenez, 2001, Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA, Synapse, 42, 12, 10.1002/syn.1095 Mahmoudi, 2013, Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia, Eur J Neurosci, 38, 2192, 10.1111/ejn.12198 Mahmoudi, 2014, Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model, Mov Disord, 29, 1125, 10.1002/mds.25909 Matosin, 2013, Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment, Schizophr Res, 146, 170, 10.1016/j.schres.2013.01.018 Matsubara, 1989, Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex, Life Sci, 45, 1397, 10.1016/0024-3205(89)90027-1 McCullumsmith, 2003, Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat, Eur J Pharmacol, 477, 101, 10.1016/j.ejphar.2003.08.018 Meador-Woodruff, 2001, Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder, Brain Res Bull, 55, 631, 10.1016/S0361-9230(01)00523-8 Meltzer, 2013, Update on typical and atypical antipsychotic drugs, Annu Rev Med, 64, 393, 10.1146/annurev-med-050911-161504 Millan, 2005, N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives, Psychopharmacology, 179, 30, 10.1007/s00213-005-2199-1 Morin, 2010, Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys, Neuropharmacology, 58, 981, 10.1016/j.neuropharm.2009.12.024 Morin, 2013, Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys, Neuropharmacology, 73, 216, 10.1016/j.neuropharm.2013.05.028 Morissette, 2006, Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin, Mov Disord, 21, 9, 10.1002/mds.20654 Noga, 1997, Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains, Synapse, 27, 168, 10.1002/(SICI)1098-2396(199711)27:3<168::AID-SYN2>3.0.CO;2-B Ossowska, 1999, Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats, Naunyn Schmiedebergs Arch Pharmacol, 359, 280, 10.1007/PL00005353 Ouattara, 2010, Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys, J Neurochem, 113, 715, 10.1111/j.1471-4159.2010.06635.x Ouattara, 2011, Metabotropic glutamate receptor type 5 in levodopa-induced motor complications, Neurobiol Aging, 32, 1286, 10.1016/j.neurobiolaging.2009.07.014 Pappa, 2010, Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study, Clin Neuropharmacol, 33, 271, 10.1097/WNF.0b013e3181ffde32 Parent, 1995, Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop, Brain Res Brain Res Rev, 20, 91, 10.1016/0165-0173(94)00007-C Paxinos, 2009 Purves-Tyson, 2017, Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain, Transl Psychiatry, 7, e1003, 10.1038/tp.2016.257 Rana, 2013, New and emerging treatments for symptomatic tardive dyskinesia, Drug Des Devel Ther, 7, 1329, 10.2147/DDDT.S32328 Reader, 1998, Neuroleptics and dopamine transporters, Neurochem Res, 23, 73, 10.1023/A:1022405621365 Rehavi, 1998, Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones, Brain Res Mol Brain Res, 57, 31, 10.1016/S0169-328X(98)00058-8 Rehavi, 2002, Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2, Eur Neuropsychopharmacol, 12, 261, 10.1016/S0924-977X(02)00021-4 Riahi, 2011, Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias, Eur J Neurosci, 33, 1823, 10.1111/j.1460-9568.2011.07675.x Rivest, 1995, Brain dopamine transporter: gender differences and effect of chronic haloperidol, Brain Res, 692, 269, 10.1016/0006-8993(95)00611-S Rodriguez-Oroz, 2009, Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms, Lancet Neurol, 8, 1128, 10.1016/S1474-4422(09)70293-5 Ryu, 2015, Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study, J Clin Psychopharmacol, 35, 13, 10.1097/JCP.0000000000000250 Samadi, 2008, MGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys, Neurobiol Aging, 29, 1040, 10.1016/j.neurobiolaging.2007.02.005 Sanchez, 2011, Estradiol modulation of cortical, striatal and raphe nucleus 5-HT1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy, Neuropharmacology, 60, 642, 10.1016/j.neuropharm.2010.11.024 Schmitt, 2003, Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits, Neurochem Res, 28, 235, 10.1023/A:1022325116309 Schoonover, 2017, Protein markers of neurotransmitter synthesis and release in postmortem schizophrenia substantia nigra, Neuropsychopharmacology, 42, 540, 10.1038/npp.2016.164 Seeman, 2013, Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia, Prog Neuropsychopharmacol Biol Psychiatry, 44, 178, 10.1016/j.pnpbp.2013.02.011 Sgambato-Faure, 2012, Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease, Prog Neurobiol, 96, 69, 10.1016/j.pneurobio.2011.10.005 Spurney, 1999, Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats, Synapse, 34, 266, 10.1002/(SICI)1098-2396(19991215)34:4<266::AID-SYN3>3.0.CO;2-2 Tamminga, 1990, Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains, Psychopharmacology, 102, 474, 10.1007/BF02247127 Tamminga, 1994, Clozapine in tardive dyskinesia: observations from human and animal model studies, J Clin Psychiatry, 55, 102 Turrone, 2002, The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy?, Neurosci Biobehav Rev, 26, 361, 10.1016/S0149-7634(02)00008-8 Van Oekelen, 2003, 5-HT2A and 5-HT2C receptors and their atypical regulation properties, Life Sci, 72, 2429, 10.1016/S0024-3205(03)00141-3 Wilmot, 1989, Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain, Brain Res, 487, 288, 10.1016/0006-8993(89)90833-0 Yoder, 2004, Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia, Schizophr Res, 71, 371, 10.1016/j.schres.2004.03.015 Zai, 2013, Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia, J Psychiatr Res, 47, 1760, 10.1016/j.jpsychires.2013.07.025 Zhang, 2007, Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue, J Chromatogr B Analyt Technol Biomed Life Sci, 858, 276, 10.1016/j.jchromb.2007.08.007